top of page

What You Need to Know About Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)


Breast augmentation has been a popular cosmetic procedure for many, boosting self-confidence and body image. However, concerns have emerged regarding a rare condition known as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in recent years. What's all these concerns about? Should ladies still put in implants? Should the ladies with implants with them have them removed? Let's break down some key questions about this condition in a way that's easy to understand.


Q1. When did we start noticing BIA-ALCL?

A1. The FDA first noted a potential link between breast implants and ALCL (Anaplastic Large Cell Lymphoma) in 2011. At that time, cases were so rare that determining risk factors was challenging. In 2016, the World Health Organization officially designated it as BIA-ALCL, emphasizing the difficulty in determining exact case numbers due to global reporting limitations.


Q2. What is BIA-ALCL, and is it breast cancer?

A2. BIA-ALCL is not breast cancer but a type of non-Hodgkin's lymphoma, specifically affecting the immune system. It is typically found in the scar tissue and fluid near the implant but, in some cases, can spread. Although the risk is considered low, it's a serious condition that can be fatal if not treated promptly. Treatment often involves surgical removal of the implant and surrounding tissue, sometimes followed by chemotherapy and radiation.


Q3. What are the symptoms of BIA-ALCL?

A3. The main symptoms include persistent swelling, a mass, or pain around the breast implant. These symptoms may appear years after the surgery, even after the incision has healed. Healthcare providers often observe fluid accumulation around the implant (seroma), and patients may notice lumps under the skin or thick scar capsules.


Q4. Where in the breast is BIA-ALCL found?

A4. BIA-ALCL is usually found near the implant, within the fibrous scar capsule, not in the breast tissue itself. Cases commonly involve ALCL cells in the fluid around the implant or within the scar capsule.


Q5. Does the implant's surface texture impact the risk of BIA-ALCL?

A5. Textured implants pose a higher risk than smooth ones, according to growing evidence. Certain textured products, including tissue expanders, are now discouraged. Patients and healthcare providers are advised to stay informed about these recommendations.


Q6. Could textured tissue expanders increase the risk of BIA-ALCL?

A6. Certain textured tissue expanders are of concern, and the FDA recommends against their use. Patients are encouraged to discuss alternatives with their healthcare providers. The long-term impact of temporary exposure to these expanders on BIA-ALCL risk is not fully understood.


Q7. Does the type of implant fill (silicone vs. saline) affect the risk of BIA-ALCL?

A7. Current data suggests that the implant's fill type does not appear to be a risk factor, but more research is needed for a definitive conclusion.


Q8. What should healthcare professionals and patients do?

A8. Healthcare professionals should discontinue the use of specific implants and tissue expanders, following FDA recommendations. Patients are advised to be aware of BIA-ALCL symptoms and seek medical attention if they experience any changes.


Q9. What should individuals considering breast implants do?

A9. Individuals considering breast implants should thoroughly evaluate the benefits and risks, discussing goals and expectations with their surgeon.


Q10. What do the latest statistics tell us about BIA-ALCL?

As of June 30, 2023, FDA has received a total of 1264 U.S. and global medical device reports of BIA-ALCL. The median age at time of diagnosis was 53 years and the median time from the last implant to diagnosis was 8 years. 73% of reported caes have textured surface implants. 48% presented with seroma, 25% with breast swelling / pain, 14% with capsular contracture, and 11% with a peri-implant mass / lump.


CONCLUSION

BIA-ALCL is a rare occurrence. Staying informed and proactive is essential for both healthcare professionals and patients but there is no need to panic. So far, there has been no recommendation by FDA or any professional bodies to remove implants proactively. However, regular check-ups, awareness of symptoms, and open communication with healthcare providers are crucial for the safety of those considering or already having breast implants.

30 views0 comments

Comments


bottom of page